[Project of invention] [ERBISOL®] [Extra ERBISOL®] [ERBISOL ® UItrapharm] [Publications] [Recomendations] [Doctors' Experience] [Dissertations] [Contact] [News]

| Greeting | | Conception of invention | | Patents | | General description of preparations of class of Erbisol® |

Erbisol - inspector and restorer

Drug preparations of ERBISOL®

Immunomodulators   АТС code L03A X  +


ATC A16A X10
Facilities, operating on metabolic processes

Antiviral facilities for system application




Highly effective drug preparations of new generation with original mechanism of action


Preparations of ERBISOL® class in the composition contain the low-molecular “signal” fragments of membrane glycoproteins, executing the function of “markers of physiological state of cell ”, which at pathological disturbances of homoeostasis activate the natural evolutionary formed controlling systems of organism, responsible for a search and removal of pathological changes in organs and tissues.

The immune system system is one of such systems.

Composition: complex of natural nonprotein low-olecular organic compounds of nonhormonal origin, obtained from animal embryonal tissue; the drug preparations contains glycopeptides, oligopeptides, nucleotides and amino acids in 0,9 % NaCl solution.


Specificity of immune modulating properties of ERBISOL® drug preparations:


1  - they activate cells of macrophagal row, participating in reparation of damaged cells and regeneration of organs and tissues with restoration of their functional activity;

2 - they activate killer cells (N- and Т-killers) responsible for elimination of damaged cells, unfit for regeneration or anomalous cells (mutant, malignant, viruliferous) and tissues;

3 - they are   immunocorrectors: normalize the activity of Тh1- and Тh2-lymphocytes and restore cytokine balance, thus harmonizing the state of cellular and humoral immunity, and inhibit the course of autoimmune and allergic processes.





the elimination of anomalous  and the restoration of damaged cells and tissues


ERBISOL® drug preparations influence ONLY on disbalanced systems, injured organs and tissues, remaining almost indifferent to healthy organism, and causing no adverse effects, i.e. the products are safe, induce no drug poisoning in overdose or after prolonged use. They are excellent facilities in disease prevention.


The preparations raise protective and adaptive funkcion of organism.
They will help you to unlock your physiological potential for full-fledged life.


ERBISOL®, as an immunomodulator influence equally on cells of macrophagal ,
and killer
row (N- and Т-killers), possesses immunocorrective properties.

It is intended for wide application.




 Exrta ERBISOL®, as an immunomodulator activates generallymacrophages. In this connection, it is intended for intensification of reparation of damaged cells and regeneration of organs and tissues by restoration of their functional activity, which is especially effective in treatment of the diseases of nervous, endocrine and cardiovascular systems.





ERBISOL® ULTRAfarm activates generally killer cells (N- and Т-killers, cytotoxic CD8+-Т-lymphocytes), Th1-lymphocytes and, partly, macrophages; it induces the synthesis of α-, β- and γ-interferon, interleukin (IL)-2 and IL-12, and tumor necrosis factor (TNF)- α; it is an effective immunocorrector.

The basic orientation of ERBISOL® ULTRAfarm action is related with intensification of antiviral and antitumorous protection of organism.





Specific of influence each of these preparations allows to combine their application on the different stages of therapy of pathological process.

So, at therapy of viral diseases on the first stage of treatment ERBISOL® ULTRAfarm
apply for elimination of causative agent, and then ERBISOL®is used for the regeneration of the damaged tissue.


At therapy of cancer diseases on the first stage is usually applied chemo- or radial therapy, which is desirable to conduct escorted by preparation ERBISOL®, which promotes to reparation of normal cells and tissues, damaged by chemotherapy. After the courses of chemo- or radial therapy apply immunotherapy by preparation


At therapy of diabetes mellitus on the first stage ERBISOL®
apply for the stop of autoimmune process, and then
is used as most active repairer.


Exclusive ownership on drug preparations of ERBISOL® class are protected in 20 countries of the world by international patent applications РСТ/UA93/00003 and РСТ/UA93/00004, including: Europatent N 0673652, US patents N 8/397288, patent of Russia N 2041715, patent of Ukraine N 2164, patent of Belarus N2039, patent of Poland N173321, patent of Bulgaria N 61679… .

Term of action of patents – 20 years, from 21.07.1992.


In 1994 preparation of ERBISOL® has been registered by Ministry of Health of Ukraine and added in a register of vitally necessary medicines of Ukraine.


 In 2001 Ministry of Health of Ukraine has registered preparation of  Extra ERBISOL®,


 In 2005 - preparation  ERBISOL® ULTRAfarm.


PART   2

Immunomodulating properties of drug preparations of ERBISOL® class

The effect of drug preparation of ERBISOL® class on expression of blood leukocyte antigens (I) and cytokine synthesis by mononuclear cells (II) in healthy donors (а) and cancer patients (b) in vitro relatively their spontaneous level (activation coefficient).


The drug preparations render minimal influence to expression of blood leukocytes antigen in healthy donors. In this case, Extra ERBISOL® activates in a greater degree 1) monocytes, intensifying reparation and regeneration processes, 2) N-killers, activating non-specific cellular immunity and reduces 3) the activity of В-lymphocytes, thus inhibiting humoral immunity (Fig. Іа), that generally provides the complete process of regeneration with removal of anomalous cells. ERBISOL® ULTRAfarm render maximal effect on expression of leukocyte antigen in oncopathology.

The preparations of  ERBISOL® class stimulate synthesis of IL-2, TNF-α, α-, β- and γ-IFN and inhibit synthesis of IL-4 and IL-10 by blood leukocytes in both healthy donors and cancer patients. The preparations increase IL-1 synthesis by blood leukocytes in healthy donors and decrease pathologically high IL-1 level in cancer patients.


Acrobat Reader 5.0+ is necessary to view PDF files

| Greeting | | Conception of invention | | Patents | | General description of preparations of class of Erbisol® |

[Project of invention] [ERBISOL®] [Extra ERBISOL®] [ERBISOL ® UItrapharm] [Publications] [Recomendations] [Doctors' Experience] [Dissertations] [Contact] [News]